NICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with untreated lung cancer, in combination with chemotherapy.
AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck
Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC).
Roche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple negative breast cancer, and untreated lung cancer, as the company plays catch-up with